XDNA
Closed
Kelly Crispr & Gene Editing Technology Etf
7.38
-23.04 (-75.74%)
Last Update: 13 Dec 2023 17:30:00
Yesterday: 30.42
Day's Range: 7.38 - 7.38
Send
sign up or login to leave a comment!
When Written:
8.86
The Kelly CRISPR & Gene Editing Technology ETF is an exchange-traded fund that invests in companies that are involved in the development and application of CRISPR and gene editing technologies. CRISPR is a revolutionary gene editing tool that allows scientists to make precise changes to DNA, and it has the potential to revolutionize medicine, agriculture, and other fields.
The ETF is managed by Kelly Asset Management and was launched in 2020. It holds a diversified portfolio of companies that are involved in CRISPR and gene editing technologies, including companies that develop gene therapies, gene editing tools, and gene sequencing technologies.
Some of the top holdings in the Kelly CRISPR & Gene Editing Technology ETF include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Illumina, and Thermo Fisher Scientific.
Investing in the Kelly CRISPR & Gene Editing Technology ETF provides investors with exposure to the rapidly growing field of gene editing and the potential for significant returns. However, like all investments, it also carries risks, including the risk of market volatility and the risk of investing in emerging technologies that may not live up to their potential.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The ETF is managed by Kelly Asset Management and was launched in 2020. It holds a diversified portfolio of companies that are involved in CRISPR and gene editing technologies, including companies that develop gene therapies, gene editing tools, and gene sequencing technologies.
Some of the top holdings in the Kelly CRISPR & Gene Editing Technology ETF include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Illumina, and Thermo Fisher Scientific.
Investing in the Kelly CRISPR & Gene Editing Technology ETF provides investors with exposure to the rapidly growing field of gene editing and the potential for significant returns. However, like all investments, it also carries risks, including the risk of market volatility and the risk of investing in emerging technologies that may not live up to their potential.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!